Anelixis Therapeutics, Inc. — Form D
Anelixis Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2017-06-20. The offering totals $8.0M, of which $4.3M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2017-06-20
- Form: D
- Accession: 0001704400-17-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $8.0M
- Amount sold: $4.3M
- Remaining: $3.7M
- Investors: 4
- Date of first sale: 2017-06-05
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-289051
Issuer
- Name: Anelixis Therapeutics, Inc.
- CIK: 0001704400
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 300 TECHNOLOGY SQUARE, SUITE 400, CAMBRIDGE, MA, 02139
- Phone: 617-441-7200
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Kent Bransford | Director | CAMBRIDGE, MA |
| Eric Craven | Director | CAMBRIDGE, MA |
| James Heywood | Director | Cambridge, MA |
| Theodore Reich | Director | CAMBRIDGE, MA |
| Paul Sallaberry | Director | CAMBRIDGE, MA |
| Steven Perrin | Director | Irvine, CA |
| Steven Perrin | Executive Officer | Irvine, CA |
| Walter Ogier | Director | Irvine, CA |
| Maeve McNally | Executive Officer | Cambridge, MA |
| Augie Nieto | Director | Cambridge, MA |
| WALTER C OGIER | Director | CAMBRIDGE, MA |
| MAEVE C MCNALLY | Executive Officer | CAMBRIDGE, MA |
Other filings by this issuer (2)
More